A pharmaceutical composition for preventing and treating angina pectoris of coronary heart disease and its application

A technology of coronary heart disease angina pectoris and composition, which is applied in the field of medicine to achieve the effect of increasing patient compliance, increasing safety, and increasing NO content

Inactive Publication Date: 2016-03-02
纪村传
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, in the treatment of coronary heart disease, there is no literature report on drugs that use p-hydroxyephrine or the combination of p-hydroxyephrine and nitroglycerin as the main active ingredient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition for preventing and treating angina pectoris of coronary heart disease and its application
  • A pharmaceutical composition for preventing and treating angina pectoris of coronary heart disease and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1 Effect of Nitroglycerin Combined with Paraxyephrine on Serum NO Content in Rats with Acute Myocardial Ischemia

[0018] 50 healthy Wistar rats, weighing 220-250g, male, were randomly divided into the following five groups: normal control group, model control group, nitroglycerin group, p-hydroxyephrine group and combined drug group, 10 in each group. Taking the rat body weight as the benchmark, the rats in the nitroglycerin group were intravenously injected with nitroglycerin 0.2 mg / kg, the rats in the p-hydroxyephrine group were injected with 20 mg / kg p-hydroxyephrine intravenously, and the rats in the combined drug group were injected with nitroglycerin 0.1 mg / kg intravenously. kg and 10 mg / kg of p-hydroxyephrine, the model control group and the normal control group were intravenously injected with equal volume of normal saline. Each group was injected once a day between 9:00 and 10:00 am for 7 consecutive days. Ten minutes after the injection on the 5th, 6...

Embodiment 2

[0024] Example 2 Effect of nitroglycerin combined with oxyephrine on hypoxic tolerance time in acute myocardial ischemia mice

[0025] 50 healthy Kunming mice, weighing 18-22g, half male and half male, were randomly divided into the following five groups: normal control group, model control group, nitroglycerin group, p-hydroxyephrine group and combined drug group, 10 mice in each group . Based on the body weight of the mice, the mice in the nitroglycerin group were intravenously injected with 0.3 mg / kg of nitroglycerin, the mice in the p-hydroxyephrine group were injected with 30 mg / kg of p-hydroxyephrine intravenously, and the mice in the combined drug group were injected with 0.15 mg / kg of nitroglycerin intravenously. kg and 15 mg / kg of p-hydroxyephrine, the model control group and the normal control group were intravenously injected with equal volume of normal saline. Each group was injected once a day between 9:00 and 10:00 a.m. for 8 consecutive days. Ten minutes after...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicine composition for preventing and treating the angina pectoris of the coronary heart disease and an application thereof. The medicine composition comprises synephrine and nitroglycerin, wherein the weight ratio of the synephrine to the nitroglycerin is (80-150):1. The medicine composition disclosed by the invention has the advantages that the content of NO in serum of a patient can be increased synergistically, and the anti-hypoxia time of the patient can be prolonged, so that the purpose of resisting the myocardial ischemic coronary heart disease is achieved.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for preventing and treating angina pectoris of coronary heart disease and its application. Background technique [0002] Coronary atherosclerotic heart disease is a heart disease caused by atherosclerotic lesions in the coronary arteries that cause stenosis or blockage of the vessel lumen, resulting in myocardial ischemia, hypoxia or necrosis. It is often called "coronary heart disease". There are many types of coronary heart disease, including coronary heart disease and angina pectoris. The basic pathology of coronary heart disease angina pectoris is coronary insufficiency, myocardial acute, temporary ischemia and hypoxia. Studies in recent years have shown that NO has strong vasodilation, inhibition of vascular smooth muscle cell proliferation, anti-platelet aggregation, adhesion and release of active substances, and can prevent vasosp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/21A61P9/10A61K31/137
Inventor 纪村传刘中立赵丽华李威
Owner 纪村传
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap